Literature DB >> 15504871

Anti-Aspergillus fumigatus efficacy of pentraxin 3 alone and in combination with antifungals.

Roberta Gaziano1, Silvia Bozza, Silvia Bellocchio, Katia Perruccio, Claudia Montagnoli, Lucia Pitzurra, Giovanni Salvatori, Rita De Santis, Paolo Carminati, Alberto Mantovani, Luigina Romani.   

Abstract

The collectin pentraxin 3 (PTX3) is an essential component of host resistance to pulmonary aspergillosis. Here we examined the protective effects of administration of PTX3 alone or together with deoxycholate amphotericin B (Fungizone) or liposomal amphotericin B (AmBisome) against invasive aspergillosis in a murine model of allogeneic bone marrow transplantation. PTX3, alone or in combination with the polyenes, was given intranasally or parenterally either before, in concomitance with, or after the intranasal infection with Aspergillus fumigatus conidia. Mice were monitored for resistance to infection and parameters of innate and adaptive T-helper immunity. The results showed the following: (i) complete resistance to infection and reinfection was observed in mice treated with PTX3 alone; (ii) the protective effect of PTX3 was similar or superior to that observed with liposomal amphotericin B or deoxycholate amphotericin B, respectively; (iii) protection was associated with accelerated recovery of lung phagocytic cells and T-helper-1 lymphocytes and concomitant decrease of inflammatory pathology; and (iv) PTX3 potentiated the therapeutic efficacy of suboptimal doses of either antimycotic drug. Together, these data suggest the potential therapeutic use of PTX3 either alone or as an adjunctive therapy in A. fumigatus infections.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15504871      PMCID: PMC525434          DOI: 10.1128/AAC.48.11.4414-4421.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  46 in total

Review 1.  Host defense mechanism in Aspergillus fumigatus infections.

Authors:  M Schneemann; A Schaffner
Journal:  Contrib Microbiol       Date:  1999

2.  Pathologic manifestations of invasive pulmonary aspergillosis in cancer patients: the many faces of aspergillus.

Authors:  B A Babbin; J N Greene; R Vega; S Iravani; N N Ku; R L Sandin
Journal:  Cancer Control       Date:  2000 Nov-Dec       Impact factor: 3.302

Review 3.  New approaches to invasive fungal infections.

Authors:  Kieren A Marr
Journal:  Curr Opin Hematol       Date:  2003-11       Impact factor: 3.284

4.  Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients.

Authors:  B Muller; G Peri; A Doni; V Torri; R Landmann; B Bottazzi; A Mantovani
Journal:  Crit Care Med       Date:  2001-07       Impact factor: 7.598

Review 5.  AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience.

Authors:  Jill Adler-Moore; Richard T Proffitt
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

Review 6.  Fungal infections after bone marrow transplant.

Authors:  J R Wingard
Journal:  Biol Blood Marrow Transplant       Date:  1999       Impact factor: 5.742

7.  T cell vaccination in mice with invasive pulmonary aspergillosis.

Authors:  E Cenci; A Mencacci; A Bacci; F Bistoni; V P Kurup; L Romani
Journal:  J Immunol       Date:  2000-07-01       Impact factor: 5.422

8.  The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism.

Authors:  Keya Sau; Salamatu S Mambula; Eicke Latz; Philipp Henneke; Douglas T Golenbock; Stuart M Levitz
Journal:  J Biol Chem       Date:  2003-07-14       Impact factor: 5.157

9.  Myeloid progenitors protect against invasive aspergillosis and Pseudomonas aeruginosa infection following hematopoietic stem cell transplantation.

Authors:  Andrew BitMansour; Stacy M Burns; David Traver; Koichi Akashi; Christopher H Contag; Irving L Weissman; Janice M Y Brown
Journal:  Blood       Date:  2002-08-08       Impact factor: 22.113

10.  Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies.

Authors:  Holger Hebart; Claudia Bollinger; Paul Fisch; Jacqueline Sarfati; Christoph Meisner; Manuela Baur; Jürgen Loeffler; Michel Monod; Jean-Paul Latgé; Hermann Einsele
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

View more
  48 in total

1.  Role of innate immune receptors in paradoxical caspofungin activity in vivo in preclinical aspergillosis.

Authors:  Silvia Moretti; Silvia Bozza; Carmen D'Angelo; Andrea Casagrande; Maria Agnese Della Fazia; Lucia Pitzurra; Luigina Romani; Franco Aversa
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

2.  Standardization of an experimental murine model of invasive pulmonary aspergillosis.

Authors:  Donald C Sheppard; John R Graybill; Laura K Najvar; Lisa Y Chiang; Thomas Doedt; William R Kirkpatrick; Rosie Bocanegra; Ana C Vallor; Thomas F Patterson; Scott G Filler
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

Review 3.  Aspergillus fumigatus: principles of pathogenesis and host defense.

Authors:  Tobias M Hohl; Marta Feldmesser
Journal:  Eukaryot Cell       Date:  2007-09-21

4.  Efficacy of PTX3 in a rat model of invasive aspergillosis.

Authors:  Pietro Lo Giudice; Silvia Campo; Antonio Verdoliva; Vincenzo Rivieccio; Franco Borsini; Rita De Santis; Giovanni Salvatori
Journal:  Antimicrob Agents Chemother       Date:  2010-07-12       Impact factor: 5.191

5.  Effect of PTX3 and voriconazole combination in a rat model of invasive pulmonary aspergillosis.

Authors:  Pietro Lo Giudice; Silvia Campo; Rita De Santis; Giovanni Salvatori
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

Review 6.  Aspergillus fumigatus morphology and dynamic host interactions.

Authors:  Frank L van de Veerdonk; Mark S Gresnigt; Luigina Romani; Mihai G Netea; Jean-Paul Latgé
Journal:  Nat Rev Microbiol       Date:  2017-09-18       Impact factor: 60.633

7.  The angiogenic inhibitor long pentraxin PTX3 forms an asymmetric octamer with two binding sites for FGF2.

Authors:  Antonio Inforzato; Clair Baldock; Thomas A Jowitt; David F Holmes; Ragnar Lindstedt; Marcella Marcellini; Vincenzo Rivieccio; David C Briggs; Karl E Kadler; Antonio Verdoliva; Barbara Bottazzi; Alberto Mantovani; Giovanni Salvatori; Anthony J Day
Journal:  J Biol Chem       Date:  2010-04-02       Impact factor: 5.157

8.  Disulphide-reduced psoriasin is a human apoptosis-inducing broad-spectrum fungicide.

Authors:  Kyaw Zaw Hein; Hitoshi Takahashi; Toshiko Tsumori; Yukihiko Yasui; Yasuko Nanjoh; Tetsuo Toga; Zhihong Wu; Joachim Grötzinger; Sascha Jung; Jan Wehkamp; Bjoern O Schroeder; Jens M Schroeder; Eishin Morita
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-05       Impact factor: 11.205

9.  The long pentraxin PTX3 is crucial for tissue inflammation after intestinal ischemia and reperfusion in mice.

Authors:  Danielle G Souza; Flavio A Amaral; Caio T Fagundes; Fernanda M Coelho; Rosa M E Arantes; Lirlandia P Sousa; Martin M Matzuk; Cecília Garlanda; Alberto Mantovani; Adriana A Dias; Mauro M Teixeira
Journal:  Am J Pathol       Date:  2009-03-12       Impact factor: 4.307

Review 10.  Risk stratification and immunogenetic risk for infections following stem cell transplantation.

Authors:  Agnieszka Wójtowicz; Pierre-Yves Bochud
Journal:  Virulence       Date:  2016-09-09       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.